Stable disease in renal cell carcinoma after using signal transduction inhibitors

Reviews on Recent Clinical Trials

Volumn 5, Issue 2, 2010, Pages 117-122

  George, Saby ^a   Shah, Shetal N ^b   Bukowski, Ronald M ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Functional imaging; Radiological evaluation; Renal cell carcinoma; Response evaluation

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADRENAL METASTASIS; ARTICLE; BIOLOGICAL THERAPY; CANCER SURVIVAL; CANCER THERAPY; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VOLUME;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 77952792888     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488710791233635     Document Type: Article

References (16)

1. Therasse P. Evaluation of response: new and standard criteria. Ann Oncol 2002; 13 (Suppl 4): 127.
2. George DJ, Kaelin WG, Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003; 349: 419.
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125.
4. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271.
5. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115.
7. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103.
8. Escudier B, Eisen, T, Stadler, WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312.
9. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753.
10. Foo SS AD, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol. 2004; 6: 291.
11. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 26: 4572.
12. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21: 3995.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228.
14. Juweid, ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496.
15. Hain SF, Maisey MN. Positron emission tomography for urological tumours. BJU Int 2003; 92: 159.
16. Vercellino L, Bousquet G, Baillet G, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009; 24: 137.